Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
K. Peony Yu has been appointed chief medical officer of Apollomics. Most recently, Yu was chief medical officer at Fibrogen. Apollomics has also appointed Sophie (Zhengjie) Sun, a former Merck managing director, to senior vice president of corporate development at the company’s China office.
Clinical-stage biotech company Axcella has named Alison Schecter the president of R&D. Schecter previously served as chief medical officer for Selecta Biosciences.
A. Stewart Campbell, who most recently served as senior vice president of preclinical R&D at Axial Therapeutics, has been promoted to CEO of the company. Prior to joining Axial in 2017, Campbell was head of business development at CordenPharma.
Susheel Umesh, former CEO of India’s Panacea Biotec, has been named chief commercial officer of emerging markets at Biocon Biologics.
Gerald Cox, former chief medical officer of Editas Medicine, has been named acting chief medical officer of Cyclo Therapeutics.
Chief scientific officer of Destiny Pharma, Bill Love, has been appointed to the UK Research and Innovation COVID-19 Research and Innovation Taskforce.
Wildon Farwell has been named the chief medical officer of Dyne Therapeutics. Most recently, Farwell was vice president and global head of neuromuscular diseases and medical affairs at Biogen.
Annegret Van Der Aa has been named chief scientific officer of Ermium Therapeutics. Formerly, Van Der Aa was the chief operating officer at OCTIMET Oncology.
Jon Kratochvil has signed on as the vice president for business development and licensing in North America at ERS Genomics. Prior to this new appointment, Kratochvil was director of business development and licensing at MilliporeSigma.
Bryan Stuart, chief operating officer of Fulcrum Therapeutics, has been promoted to CEO of the company. Before he joined Fulcrum in 2018, Stuart was CEO of Yarra Therapeutics.
Lilli Petruzzelli has been named senior vice president of early clinical development at Genentech. Previously, Petruzzelli was group vice president of early clinical development at Incyte.
Gritstone Oncology’s executive vice president of research and chief scientific officer, Karin Jooss, has been promoted to head of research and development. Erin Jones, Gritstone’s executive vice president of global regulatory affairs and quality, was also recently promoted to chief operating officer.
Sean Zhang has departed from his CEO position at Hengrui Therapeutics to assume the role of chief medical officer at InnoCare.
Jubilant Therapeutics has hired Luca Rastelli to assume the role of chief scientific officer. Rastelli was most recently the chief scientific officer at Kleo Pharmaceuticals.
Omnicell has named Christine Mellon executive vice president and chief people officer. Mellon was most recently chief human resources officer at CSG.
Mark Stenhouse has been enlisted to take over the role of chief operating officer at Prometheus Biosciences. Stenhouse most recently served as special adviser to the CEO of Exact Sciences.
Jason Campagna, former chief medical officer at Intercept Pharmaceuticals, has been named chief medical officer of Q32 Bio.
Rafael Holdings has recruited Ameet Mallik to be its new CEO. Mallik previously was Novartis’s executive vice president and head of U.S. oncology
Eduardo Bruno Martins is Sagimet Bioscience’s new chief medical officer. Martins comes to Sagimet from AbbVie where he was vice president of clinical development.
Nicholas Holsman has been named chief commercial officer of Ireland’s Shorla Pharma. Holsman joins Shorla from Oncopeptides, where he served as head of commercial operations.
Solid Biosciences has promoted Joel Schneider from chief technology officer to chief operating officer. Schneider was a postdoctoral fellow prior to joining Solid in 2014.
Neal Collins, former medical director at EMD Serono, has been tapped by Spaulding Clinical as its new medical director.